Retatrutide

Clinical Disclaimer: Retatrutide (LY3437943) is an investigational medication in active Phase 3 development by Eli Lilly. It is NOT FDA-approved as of April 2026. Current use outside registered clinical trials is compounded and investigational. This monograph is for qualified healthcare professionals and does not constitute prescribing guidance.

1. Introduction and Overview

Retatrutide (development code LY3437943) is a single-molecule triple-hormone-receptor agonist developed by Eli Lilly for obesity and type 2 diabetes. It is the first pharmaceutical agent to activate three incretin and counter-regulatory hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). Weight loss in Phase 2 and Phase 3 trials has exceeded both semaglutide and tirzepatide in head-to-head-comparable populations, making retatrutide the most potent incretin-based therapy in clinical development to date.

As of April 2026, the Phase 3 TRIUMPH program is ongoing, with the first trial (TRIUMPH-4, in patients with obesity and knee osteoarthritis) having reported topline results in December 2025. Eli Lilly has signaled that NDA submission will follow completion of the full Phase 3 program, with regulatory decisions anticipated in 2026–2027.

2. Pharmacology and Molecular Design

2.1 Triple-receptor mechanism

Retatrutide is a 39-residue synthetic peptide engineered to balance agonist activity across three distinct G-protein-coupled receptors, each contributing complementary effects on energy balance and metabolism:

The key innovation over tirzepatide (GLP-1 + GIP) is the addition of glucagon-receptor activity. Glucagon conventionally raises hepatic glucose output, which would worsen glycemic control — but when balanced with sufficient GLP-1/GIP-mediated insulinotropic activity, the net result is improved glucose handling plus additional weight loss driven by increased energy expenditure. Careful receptor-selectivity tuning in the retatrutide molecule balances these effects.

2.2 Pharmacokinetics

Retatrutide incorporates a C18 fatty-diacid linker that enables reversible binding to albumin, extending plasma half-life to approximately 6 days and supporting once-weekly subcutaneous dosing. Steady-state is reached in approximately 4 weeks; dose titration is required to manage gastrointestinal tolerability, typically over 16–24 weeks.

3. Clinical Evidence

3.1 Phase 2 obesity (Jastreboff et al. NEJM 2023)

The pivotal Phase 2 obesity trial randomized 338 adults without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related comorbidity, to retatrutide 1, 4, 8, or 12 mg weekly or placebo. At 48 weeks, weight loss was:

• 12 mg dose: -24.2% of baseline body weight
• 8 mg dose: -22.8%
• 4 mg dose: -17.5%
• 1 mg dose: -8.7%
• Placebo: -2.1%

The magnitude of weight loss at the 12 mg dose exceeded comparable Phase 3 semaglutide (STEP trials, ~15%) and tirzepatide (SURMOUNT-1, ~21%) results, establishing retatrutide as the most potent incretin-based weight-loss agent in clinical development at the time of publication.

3.2 Phase 2 type 2 diabetes (Rosenstock et al. Lancet 2023)

A parallel Phase 2 program in 281 adults with type 2 diabetes reported 16.9% weight loss and 2.02% absolute HbA1c reduction at the 12 mg dose over 36 weeks — again establishing best-in-class efficacy among incretin-based diabetes therapies to date.

3.3 Phase 2 metabolic-dysfunction-associated steatohepatitis (Sanyal et al. Nat Med 2024)

In adults with MASH and significant fibrosis, retatrutide demonstrated dose-dependent improvements in liver fat content and fibrosis biomarkers, supporting a Phase 3 MASH program now underway.

3.4 Phase 3 TRIUMPH program

The Phase 3 TRIUMPH program comprises 8 trials spanning obesity, type 2 diabetes, obesity with knee osteoarthritis, MASH, and heart failure with preserved ejection fraction. The first trial to report was TRIUMPH-4:

4. Prescribing Considerations

4.1 Dosing and titration

Phase 3 protocols use weekly subcutaneous dosing with monthly titration from a 2 mg starting dose through 4, 8, and 12 mg based on tolerability. Titration intervals of 4 weeks allow GI side-effect adaptation before dose escalation. Maintenance doses of 1 mg or 4 mg are used for patients unable to tolerate higher doses. The 12 mg dose is the highest studied and produces the largest weight-loss effect; lower doses retain clinically meaningful benefit with better tolerability.

Injection sites: abdomen, anterior thigh, or upper arm, rotating weekly. Prefilled pen-injectors are used in clinical trials; compounded forms outside trials use multi-dose vials with variable concentration.

4.2 Practical pearls

• Anticipate a 16–24 week titration to maximal dose; counsel patients that GI tolerability improves substantially after the first few weeks at each dose.
• Keep meal volumes smaller during titration — early satiety is part of the therapeutic effect but can cause patient distress if unexpected.
• For patients with diabetes on insulin or sulfonylureas, reduce those doses by 10–20% at retatrutide initiation to avoid hypoglycemia.
• Screen for personal or family history of medullary thyroid carcinoma — class contraindication for GLP-1 and GIP agonists.
• Plan contraception counseling for reproductive-age females; retatrutide is contraindicated in pregnancy and has a 6-day half-life, so discontinuation 2 months before planned conception is appropriate.
• Monitor for gallbladder symptoms — rapid weight loss increases cholelithiasis risk (class effect).
• Pancreatitis screening: ask about abdominal pain out of proportion to other GI effects; lipase testing only if clinically indicated.

5. Safety and Monitoring

5.1 Adverse effects

Retatrutide's safety profile is dominated by gastrointestinal effects consistent with the incretin-agonist class:

• Nausea — most common, dose-dependent, maximal during titration.
• Vomiting, diarrhea, constipation.
• Dyspepsia and early satiety (part of therapeutic mechanism).
• Fatigue, headache during titration.
• Injection-site reactions (pain, erythema, induration).
• Modest increase in heart rate (average 3–5 bpm), consistent with class.

Serious but infrequent events include acute pancreatitis (class risk), cholelithiasis and cholecystitis (rapid-weight-loss driven), hypoglycemia in patients on insulin or sulfonylureas, and acute kidney injury secondary to severe volume depletion from GI effects.

5.2 Monitoring

6. Regulatory and Sourcing

Retatrutide is not FDA-approved as of April 2026. Legitimate access is via enrollment in a registered Phase 3 TRIUMPH trial (see ClinicalTrials.gov NCT05929079, NCT05931367, NCT07035093 and related registrations). Outside trials, some 503A and 503B compounding pharmacies have begun preparing retatrutide-equivalent formulations; this practice is legally and clinically complex — compounding eligibility depends on FDA drug-shortage determinations and the specific substance's inclusion on the approved bulk-drug lists. Prescribers considering compounded retatrutide should:

• Verify current FDA shortage status before writing scripts.
• Request lot-specific Certificates of Analysis confirming peptide identity, purity (HPLC), and endotoxin testing.
• Document informed consent that reflects the investigational status and absence of FDA approval.
• Maintain awareness that compounded retatrutide supply may change abruptly when FDA-approved product launches and shortage resolves.

7. Summary and Outlook

Retatrutide is the leading next-generation incretin-based therapy — best-in-class weight-loss magnitude in Phase 2 and early Phase 3 data, active Phase 3 program spanning obesity, diabetes, liver disease, and heart failure, and anticipated FDA decisions in 2026–2027. For patients meeting Phase 3 eligibility, enrollment in an active TRIUMPH trial is the gold-standard access path. For prescribers considering compounded retatrutide outside trials, careful sourcing and informed-consent documentation are essential until FDA approval resolves the regulatory ambiguity.

Bottom line: most potent weight-loss agent in clinical development; Phase 3 data now reporting; not FDA-approved yet. Prefer trial enrollment where feasible; if compounding, verify shortage status and source rigorously.